The company recently appointed Ms Leslie Chong as managing director. As CEO, Ms Chong achieved various important milestones in both the clinical and corporate fronts.
The next steps for Imugene will be interesting, with the company this morning entering a trading halt pending details of a material acquisition, and subsequent capital raising.
Currently, Imugene's lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer.
The halt will remain in place until the opening of trade on Thursday 7 June 2018, or earlier if an announcement is made to the market.